Parkville medical precinct to grow as biotech giant CSL announces new global headquarters

Biomedical giant CSL has announced plans for a new 16-storey global headquarters in Melbourne. See what’s in store for Parkville’s medical precinct.

Parkville’s world-renowned medical research precinct is set to become even more influential with biomedical giant CSL announcing plans for a new global headquarters.

Complete with seven floors of world-class laboratories and offices for its corporate headquarters, CSL’s 16-storey development is intended to strengthen links to Melbourne’s other famed research centres.

Set on the Parkville precinct’s northern edge, CSL’s chief executive Paul Perreault said the move to 645 Elizabeth St would allow for stronger collaborations between its Australian operations and other stakeholders.

Global biotechnology leader CSL Ltd has announced plans for a new global headquarters at Parkville.

CSL’s new headquarters will allow for greater collaboration with other Parkville institutes.

Now based in Poplar Rd, at the other end of Parkville, CSL has had a presence in the precinct for more than a century but will now be geographically close to institutes including the University of Melbourne, the Walter and Eliza Hall Institute of Medical Research, the Doherty Institute for Infectious Disease, The Murdoch Children’s Research Institute, the Victorian Comprehensive Cancer Centre, the Royal Melbourne Hospital, the Royal Women’s Hospital, The Peter MacCallum Cancer Centre and the Royal Children’s Hospital.

An artist’s impression of the new CSL Limited offices in Parkville.

An artist’s impression of CSL Limited’s Parkville offices.

“Melbourne’s reputation as a world class centre of biomedical research excellence is well established,” Mr Perreault said.

“We have opportunities all around the world and R&D in several countries, but we believe the density and quality of medical research activity in Parkville has enormous future potential.

MORE NEWS:

ANTI-VAXXER IN BID TO PRACTISE MEDICINE

CALL TO TREAT FRAILTY AS A CONDITION

“As we continue to strengthen our long term collaborations with strategic partners we intend to grow these networks by further embedding key elements of our Australian operations into the nucleus of Melbourne’s medical research district.”

CSL has reached an agreement with developer PDG to build the laboratory and headquarters for 800 staff as part of its ‘Elizabeth North’ project, which includes three tower buildings.

The biomedical centre will form the second phase of the three-stage building project.

PDG managing director Vince Giuliano said the buildings will be joined by external laneways with street frontages that reflect Melbourne’s architectural heritage.

[e-mail]